Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer

Optimal salvage treatment for HER2-positive breast cancer after trastuzumab and T-DM1 failure still remains to be established. We would like to investigate the efficacy and safety of combination chemotherapy of eribulin and trastuzumab as salvage treatment for HER2-Positive breast cancer after exposure to trastuzumab and T-DM1

Trial Details

NCT ID
NCT05530057
Phase
PHASE2
Sponsor
Seoul National University Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)
  • Eribulin Mesylate
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Adults ≥18 years old.
  • Pathologically documented breast cancer that:
  • is unresectable or metastatic
  • has confirmed HER2 positive expression (immunohistochemistry or FISH) as determined according to American Society of Clinical Oncology - College of…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →